Long-Term Study of Ambrisentan in Pulmonary Hypertension

Phase 2, open-label, single-arm trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Gilead Sciences. Primary endpoints: Number of Participants With Pulmonary Arterial Hypertension (PAH) Who Completed the Phase II NCT00046319 Study and Who Experienced Severe Adverse Events (AEs) During Long-term Ambrisentan Exposure at Week 334, Number of Participants With PAH Who Completed the Phase II NCT00046319 Study and Who Experienced AEs of Moderate Severity During Long-term Ambrisentan Exposure and 1 more. Started Apr 2003; status: completed.